Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine

Pricing Availability   Qty
Cat.No. 6913 - Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine | C25H34N4O9.HCl
Description: Cereblon ligand with alkyl-PEG-alkyl linker and terminal amine for onward chemistry
Chemical Name: N-[3-[2-[2-(3-Aminopropoxy)ethoxy]ethoxy]propyl]-2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetamide hydrochloride
Purity: ≥95% (HPLC)
Datasheet
Citations
Reviews
Literature (2)

Biological Activity

Functionalized cereblon ligand for PROTAC® research and development; incorporates an E3 ligase ligand plus an alkylC1-PEG3-alkylC3 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Usage Guidelines

This product is provided for use in onward chemistry. Suitable solvents can be used.

Technical Data

M. Wt 571.02
Formula C25H34N4O9.HCl
Storage Store at -20°C
Purity ≥95% (HPLC)
Smiles NCCCOCCOCCOCCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C3CCC(NC3=O)=O)=O)=O.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References

References are publications that support the biological activity of the product.

Nabet et al (2018) The dTAG system for immediate and target specific protein degradation. Nat.Chem.Biol. 14 431 PMID: 29581585


If you know of a relevant reference for Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine, please let us know.

Keywords: Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine, Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine supplier, PROTAC, cereblon, E3, ubiquitin, ligase, PEG3, alkylC3, alkylC1, linker, conjugate, polyethylene, glycol, terminal, amine, building, blocks, components, Cereblon, Ligands, Plus, Linkers, 6913, Tocris Bioscience

Citations for Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine

Citations are publications that use Tocris products.

Currently there are no citations for Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine. Do you know of a great paper that uses Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine from Tocris? Please let us know.

Reviews for Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine

There are currently no reviews for this product. Be the first to review Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine and earn rewards!

Have you used Thalidomide 4'-oxyacetamide-alkylC1-PEG3-alkylC3-amine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Targeted Protein Degradation

Targeted Protein Degradation Research Product Guide

This brochure highlights the tools and services available from Bio-Techne to support Targeted Protein Degradation research, including:

  • Active Degraders
  • Degrader Building Blocks
  • Custom Degrader Services
  • UPS Proteins and Assays
  • Assays for Protein Degradation
Targeted Protein Degradation

Targeted Protein Degradation Poster

Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia